Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

By sjmartinez • February 7, 2023

Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan T. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023 Feb 5:e14539. doi: 10.1111/nmo.14539. Epub ahead of print. PMID: 36740814.

Tags: abdominal pain, cannabinoid receptor agonists, cannabinoids, Digestive Diseases, Irritable Bowel Syndrome, olorinab, Publications

Incidence Trends in Upper Gastrointestinal Cancer in Young Adults: A Nationwide Time-Trend Analysis Using 2001-2019 US Cancer Statistics Databases

Liang J, Rastegar R, El Helou M, Mathur K, Larson BK, Waters K, Vasireddy A, Randhawa N, Mubarak M, Advani R, Osipov A, Gong J,[...]

Oral contraceptive pill-induced esophagitis: a rare cause of pill esophagitis in a Rwandan woman

Bensen GP, Bryan MR, Nishimwe E, Nguyen BS, Chudy-Onwugaje K. Oral contraceptive pill-induced esophagitis: a rare cause of pill esophagitis in a Rwandan woman. Oxf[...]

JPEN Journal Club 92. Adjusting randomized trials

Koretz RL. JPEN Journal Club 92. Adjusting randomized trials. JPEN J Parenter Enteral Nutr. 2025 Mar 31. doi: 10.1002/jpen.2750. Epub ahead of print. PMID: 40162714.